The clinical data of 309 patients with definite multiple sclerosis were recorded in the European data base for multiple sclerosis (EDMUS) to determine the prognostic significance of several demographic and clinical variables. An interview with closed questions structured according to standardised criteria of disease phases and courses was used to assess the clinical course. The reliability was evaluated by four trained neurologists in a sample of 33 patients with multiple sclerosis. Both the within and between rater agreement on data collection was fair to high for the historical variables (K = 0.33-1). Between rater agreement was more variable for the evaluation of 12 different EDMUS event categories (K = 0-3-0.95). The predictive model for the time to reach a secondary progression showed that an age at onset older than 25 (p = 0 006) and an event at onset followed by disability >i3 on the Kurtzke expanded disability status scale (EDSS; p = 0-004) were the most unfavourable clinical variables in 249 patients with relapsing remitting (180) or relapsing progressive (69) courses. In the 69 patients with relapsing progressive disease, the time to reach severe disability (EDSS > 6) was negatively influenced by a first interval between attacks shorter than one year, a number of bouts with EDSS >2 in the first two years of the dis-
Abstract
The clinical data of 309 patients with definite multiple sclerosis were recorded in the European data base for multiple sclerosis (EDMUS) to determine the prognostic significance of several demographic and clinical variables. An interview with closed questions structured according to standardised criteria of disease phases and courses was used to assess the clinical course. The reliability was evaluated by four trained neurologists in a sample of 33 patients with multiple sclerosis. Both the within and between rater agreement on data collection was fair to high for the historical variables (K = 0.33-1). Between rater agreement was more variable for the evaluation of 12 different EDMUS event categories (K = 0-3-0.95). The predictive model for the time to reach a secondary progression showed that an age at onset older than 25 (p = 0 006) and an event at onset followed by disability >i3 on the Kurtzke expanded disability status scale (EDSS; p = 0-004) were the most unfavourable clinical variables in 249 patients with relapsing remitting (180) or relapsing progressive (69) courses. In the 69 patients with relapsing progressive disease, the time to reach severe disability (EDSS > 6) was negatively influenced by a first interval between attacks shorter than one year, a number of bouts with EDSS >2 in the first two years of the disease, and involvement of the pyramidal system at onset (p < 0.05). In 60 patients with chronic progressive disease this outcome was negatively influenced by pyramidal, brainstem, and sensory involvement at onset (p < 0-01).
sex has been associated with a more benign course in some studies' 4 and male sex in others5 6; other studies have failed to detect any correlation.7 9 Some,1 410 but not all,6-9 1' investigators found a worse outcome in those patients with an older age of onset and a short first interval between attacks.'2 The relapsing remitting disease course has been found to be more favourable than the chronic progressive course in most series.' 2 4-9 11 A high exacerbation rate seems to induce a worse prognosis in a few studies2 "' and only a few reports deal with the importance of a mild disability at five years. 1 ' More than one Kurtzke functional system'4 involved at onset seems to be a factor in worse prognosis.'1 A favourable prognosis when the presenting symptom is optic neuritis has been found by some2 [6] [7] [8] [9] [10] but not all investigators.4 l" Similarly initial sensory symptoms have been considered favourable by some,' "' but not by others.2481' The lack of uniformity of methods used in different studies to assess retrospective as well as prospective clinical events in multiple sclerosis is probably one of the major reasons for this controversy. Therefore, the use of a common language is an essential prerequisite to standardise morbidity records in patients with multiple sclerosis. In this paper we report the results of a multivariate survival analysis of predictive factors of long term disease course performed on clinical data from a hospital based series of 309 patients with definite multiple sclerosis recorded in the European data base for multiple sclerosis (EDMUS). ' (RU) . During the "sequelae period" of the same course, a distinction was made between the relapse at onset (SO) and subsequent relapses with a well identified date of onset and followed by a non-worsening (SN), or a worsening (SW), or a doubtful worsening (S?) of pre-existing sequelae and relapses with uncertain chronology (SU). During the "chronic progressive period", a distinction was made between onset without any initial relapse (POP) or with an inaugural relapse (POR) and subsequent relapses with a well identified (PR) or uncertain chronology (PU).
The disease course was defined as follows. A relapsing remitting course was defined as the occurrence of (a) phase(s) of worsening lasting less than six months followed by phase(s) of improvement or combined improvement and inactivity lasting at least one month; or (b) phase(s) of worsening lasting less than six months followed by a plateau phase lasting at least one year; or (c) phases of worsening, each lasting less than six months and each having an onset after at least one month from the maximum worsening of the previous one; the maximum worsening of the last of such phases is reached before six months from the onset of the first one; and the last of such worsening phases is followed by a phase of improvement and inactivity lasting at least one month or by a plateau phase lasting at least one year. The chronic progressive course was defined as the occurrence of (a) a progressive worsening lasting more than six months from the disease onset; or (b) phases of worsening spaced by plateau phases lasting more than one month and less than one year; the last phase of worsening is still present or starts after six months from the disease onset. The relapsing progressive course was defined as a relapsing remitting course followed by one of the two options described for the chronic progressive course.
The patient's disability was derived from the Kurtzke expanded disability status scale (EDSS)'4 at the time of examination, and it was also evaluated retrospectively for each visit during the history.
To evaluate the reliability of the clinical history, the standardised interview was initially given by PL, MT, CA, and FDR to a randomly selected sample of 33 patients with definite multiple sclerosis with disease duration ranging between two and 226 months, age between 18 and 52 years, and with an EDSS score between 0 and 7; no patients had objective signs of cognitive impairment as indicated by a mini mental state score'7 higher than 24 . All patients gave their informed consent. The between and within observer agreement rates18 were measured after one day and after one month on the main collected clinical data-namely, symptoms at onset and during the disease course, number of worsening and inactivity phases, current phase of the disease, diagnostic categories, duration of the first interval between attacks, and of the first inactivity phase. The between rater agreement on the definition of the 12 
Results
The reliability of the clinical records obtained by the combined use of the standardised interview and the EDMUS chronology form was satisfactory.20 An almost perfect between/within observer agreement (K = 1) was obtained on the definition of the diagnostic categories.18 A moderate to substantial (K = 0 53-0-8 p < 0-0001) between observer and a fair to substantial (K = 0-33-0-8 p = 0-001 to <0-0001) within observer agreement was found for the other historical variables considered. At the same time an overall moderate between rater agreement (% of agreement = 62/130; K = 0-52 p < 0-0001) was found for the evaluation of the 12 different disease event categories. The agreement was almost perfect (K = 0 95 p < 0-0001) for RO, substantial (K = 0-6-0-7 p < 0-0001) for RR and PR, moderate (K = 0A4-0 5 p < 0-0001) for SO, SN, and POP, and fair (K = 0 3-0 4 p < 0-01) for SW and S? events. Relapses with uncertain chronology in the three different course periods (RU, SU, PU) were not found. Table 1 shows the major differences in early clinical and demographic features found among the three subgroups of patients with different disease course. The distribution of disability score adjusted for duration of disease in these three subgroups showed (fig 2) that the relapsing remitting group was characterised by a significantly (Fisher's exact test, p < 0-0001) higher frequency of a mild disability and a lower frequency of severe disability than the relapsing progressive and chronic progressive groups. This was irrespective of whether patients had a duration of disease less than five years, between five and 10 years, or more than 10 years. For the distribution of functional systems involved at the onset of the disease (fig 3) , the chronic progressive course was characterised by a significantly higher frequency of pyramidal (84%), mental (13%), and sphincteric (16%) symptoms and a lower frequency of brainstem (7%) and visual (8%) involvement than relapsing remitting and relapsing progressive courses. The predictive value of the aforementioned variables for the time to reach secondary progression was evaluated in the relapsing remitting and relapsing progressive groups together. The multivariate predictive model (table 2) showed that, despite the great number of censored patients (72%), an age at onset older than 25 years (p = 0-006) and an event at onset with sequelae (p = 0-04) seemed the most unfavourable clinical variables. Figure 4 gives the survival curves showing the probability of patients not having reached progression after stratification according to age at onset older or younger than 25 years and the presence or absence of a disease event at onset with sequelae. The greatest differences were found in the groups with age at onset less than 25 years with or without sequelae after the event at onset (A and B) compared with the group with age of onset more than 25 years and sequelae (D). When the time to reach EDSS 6 was considered as the end point, relapsing progressive and chronic progressive groups were analysed separately because of the significant difference in survival curves ( fig 5) . These showed that a higher percentage of patients with relapsing progressive multiple sclerosis than those with chronic progressive multiple sclerosis had not reached this disability stage during the follow up time (log rank p = 0-02; Wilcoxon p = 0 02). In relapsing progressive disease, the multivariate predictive model showed (table 3) that an interval between first attacks shorter than one year, a number of bouts higher than 2 in the first two years of the disease, and a pyramidal involvement at onset reduced the time to severe disability significantly (p < 0 05). In the chronic progressive group (table 4) the involvement of pyramidal, brainstem, and sensory systems at the onset of disease were significantly (p < 0-01) associated with the same adverse outcome. 
Discussion
These data show that the combined use of a standardised interview structured according to definite criteria for temporal limits of disease phases and courses'6 and a precise classification of disease events such as proposed in the EDMUS'5 allows us to obtain a good within and between observer agreement in collection of historical multiple sclerosis data. More than 100 clinical events were scored and for all of them the K index was good.
Relapses without sequelae were recognised with a high degree of agreement, both when occurring at the onset (RO) or during the disease course itself (RR); when the relapses were followed by sequelae (SO, SN) the agreement was still significant, but less so, particularly in the case of relapse with worsening (SW) and relapse with doubtful worsening (S?); relapses were well identified also when superimposed during the progressive course (PR). It is worthwhile noting that relapses Table 2 Multivariate analysis predicting the time to reach secondary progression in 249 patients with definite multiple sclerosis with relapsing remitting (180) and relapsing progressive (69) Time (months) Figure 4 Survival probability ofpatients not having reached progression after stratification according to the age at onset and to the presence of a first disease event with sequelae. A = age at onset < 25 y; disease event at onset without sequelae; B = age at onset < 25 y; disease event at onset with sequelae; C = age at onset > 25 y; disease event at onset without sequelae; D = age at onset > 25 y; disease event at onset with sequelae. Weibull scale parameter = 0-5 (0-08); % censored cases = 46.
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with "uncertain chronology" (RU, SU, PU) during the three different course periods ("no sequelae", "sequelae" and "chronic progressive") were not found in this series by 
